Key result
ABI-LOW and multivessel scoring link to ~87% higher mortality but offer limited predictive value in hypertension.
Why the study?
While alternative ABI calculations have improved sensitivity for PAD detection, their prognostic utility in hypertensive populations remains unclear.
Do alternative ankle-brachial index assessments (ABI-LOW and multivessel scoring) improve mortality risk prediction compared to standard ABI in hypertensive patients?
Do alternative ankle-brachial index assessments (ABI-LOW and multivessel scoring) improve mortality risk prediction compared to standard ABI in hypertensive patients?
While alternative ABI calculations identify more peripheral artery disease cases in hypertensive patients, they offer limited incremental value over standard clinical predictors for predicting all-cause mortality.
Alternative ABI methods identify more PAD without meaningfully improving mortality prediction; leaves open their role in hypertensive risk stratification.
Background: Peripheral artery disease (PAD), assessed via the ankle–brachial index (ABI), is a recognized form of hypertension-mediated organ damage (HMOD). While alternative ABI calculations have shown improved sensitivity for PAD detection, their prognostic utility in hypertensive populations remains unclear. Methods: In this prospective cohort study of 21 875 hypertensive individuals (ÉRV Study), we compared the prognostic performance of three ABI-based approaches: standard ABI using the higher ankle pressure (ABI-HIGH), ABI using the lower ankle pressure (ABI-LOW), and multivessel ABI scoring (number of vessels with ABI ≤0.90). The primary endpoint was all-cause mortality, assessed over a median follow-up of 5 years using interval-censored Cox regression. Results: PAD prevalence was 14.4% using ABI-HIGH and 28.3% using ABI-LOW, with 13.9% of patients identified only by the latter. All PAD definitions were independently associated with mortality. ABI-LOW as a continuous variable demonstrated the strongest association (hazard ratio 1.87; 95% CI, 1.63–2.16). Multivessel ABI showed a dose–response relationship with mortality. However, overall discrimination was modest: time-dependent AUCs ranged from 0.608 to 0.635 for ABI-based models alone. When added to clinical predictors, ABI metrics improved the AUC to a range from 0.763 to 0.780, with added predictive value between 6 and 11%. Conclusion: In hypertensive individuals, ABI-LOW and multivessel scoring identify more PAD cases and are independently associated with mortality. However, their incremental value in mortality risk prediction is limited. Alternative ABI methods may assist in identifying higher risk subgroups warranting further vascular assessment.
No takes yet. Share an insight, caveat, or question.
Kolossváry et al. (2026) studied this question. Using ABI-LOW and multivessel ABI scoring identifies more PAD cases and associates with mortality (HR 1.87), but adds limited predictive value (AUC improvement 6-11%) in hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: